Tiotropium bromide: additional options for the treatment of bronchial asthma

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Bronchial asthma (BA) is one of the most common chronic diseases, characterized by airway inflammation and bronchospasm. Symptoms of BA are wheezing, shortness of breath, a feeling of constriction in the chest and cough, the frequency and severity of which vary greatly over time. Today studies of BA phenotypes allow selecting treatment depending on the particular pathogenesis of each phenotype individually, thereby helping to achieve control, which is the main goal of BA therapy. However, it is necessary to take into account the peculiarities of airway innervation, since an increased parasympathetic tone is characteristics of all BA phenotypes and plays an important role in the development of bronchoconstriction and inflammation. Therefore, tiotropium bromide, which is a long-acting blocker of muscarinic cholinergic receptors, is one of the main bronchodilators in the treatment of BA. It blocks bronchoconstriction, hypersecretion and swelling of the mucous membrane of the airway, which in turn prevents the progression of inflammation, and the prolonged action of tiotropium bromide, which allows it to be used once a day helps to achieve control of asthma in addition to basic inhalation therapy - inhaled corticosteroids (ICS) long-acting P2-agonists (LABA). According to GINA (Global Initiative for Asthma), tiotropium bromide is recommended as an additional treatment, starting from step 4, and in accordance with the Russian Federal Clinical Guidelines for Bronchial Asthma - from step 3. Currently, according to clinical studies, much is known about the mechanisms of action and biological properties of tiotropium bromide, which made it possible to substantiate the needs for its administration to patients with BA regardless of its phenotype. This strategy will contribute to a more successful control of BA considering risk factors and comorbidity, thereby reducing needs of increasing ICS dose.

Restricted Access

O M Kurbacheva

NRC Institute ofImmunology FMBA of Russia

M E Dyneva

NRC Institute ofImmunology FMBA of Russia

Email: amanturliva.miramgul@mail.ru

  1. Boulet LP, Boulay МЕ. Asthma-related comorbidities. Expert Rev Respir Med. 2011;5:377-393. doi: 10.1586/ers.11.34.
  2. Курбачёва ОМ, Швец СМ. Бронхиальная астма: как правильно начать лечение больного. Астма и аллергия. 2015;(2):12-18
  3. Курбачёва ОМ, Павлова КС. Фенотипы и эндотипы бронхиальной астмы: от патогенеза и клинической картины к выбору терапии. Российский Аллергологический Журнал. 2003;(1):15-24
  4. Wijnant SRA, Lahousse L., Buyzere ML, Buyzere ML, Brusselle GG, Rietzschel ER. Prevalence of Asthma and COPD and Blood Eosinophil Count in a Middle-Aged Belgian Population. Journal of Clinical Medicine. 2019;8:1-12. doi: 10.3390/jcm8081122.
  5. Osborne ML, Pedula KL, O’Hollaren M., Ettinger KM, Stibolt T., Buist AS. Assessing Future Need for Acute Care in Adult Asthmatics. The Profile of Asthma Risk Study: A Prospective Health Maintenance Organization-Based Study. Chest. 2007;132:1151-1161. doi: 10.1378/chest.05-3084.
  6. Global initiative for asthma. Global strategy for asthma management and prevention. Update 2017. http://www. ginasthma.org Acessed August, 22, 2019.
  7. Partridge Mr, Molen T. Van Der, Myrseth S., Busse WW Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmonary Medicine. 2006;6:1-9. doi: 10.1186/1471-2466-6-13.
  8. Liccardi G., Salzillo A., Calzetta L., Ora J., Cazzola M., Matera MG, Rogliani P. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? J. Allergy Clin Immunol Pract. 2016;4:791-793. DOI: 10.1016/j. jaip.2016.03.025.
  9. Курбачёва ОМ, Павлова КС. Возможно ли улучшение контроля бронхиальной атсмы без увеличения доз глюкокортикостероидов? Практическая пульмонология. 2017;(2):14-21
  10. Yoshida M., Kaneko Y., Ishimatsu A., Komori M., Iwanaga T., Inoue H. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. Pulm Pharmacol Ther. 2016;42:7-12. doi: 10.1016/j.pupt.2016.11.004.
  11. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Pineiro А., Wei LX et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group Ann Intern Med. 1999;130:487-495. doi: 10.7326/0003-4819-130-6-199903160-00005.
  12. Barnes PJ, Belvisi MG, Mak JCW, Haddad E., Connor BO. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sciences. 1995;56:853-859. doi: 10.1016/0024-3205(95)00020-7.
  13. Barnes PJ. Muscarinic receptor subtypes in airways. Life Scienc-es.1993;6:521-527. doi: 10.1016/0024-3205(93)90310-y.
  14. Bonini M., Scichilone N. Tiotropium in asthma: back to the future of anticholinergic treatment. Clin. Mol. Allergy. 2017;15(20):1-11. doi: 10.1186/s12948-017-0076-1.
  15. Verbout NG, Jacoby DB, Gleich GJ, Fryer AD. Atropine-enhanced, antigen challenge-induced airway hyperreactivity in guinea pigs is mediated by eosinophils and nerve growth factor. Am J. Physiol Lung Cell Mol Physiol. 2009;297:228-237. doi: 10.1152/ajplung.90540.2008.
  16. Meurs H, Oenema TA, Kistemaker LEM, Gosens R. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13:316-323. DOI: 10.1016/j. coph.2013.04.004.
  17. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003;98:59-69. DOI: 10.1016/ S0163-7258(03)00004-4.
  18. Chari MV, McIvor RA. Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives. Canadian Respiratory Journal. 2018;2018:1-10. doi: 10.1155/2018/3464960.
  19. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117:635-665. doi: 10.1378/chest.117.2_suppl.63s.
  20. O’connor BJ, Lesley JT, Peter JB. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med Vol. 1996;154:876-880.
  21. Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, Kohno N. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J. 2008;31:1379-1380. doi: 10.1183/09031936.00014108.
  22. Fardon T, Haggart K, Lee DKC, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med. 2007;101:1218-1228. doi: 10.1016/j.rmed.2006.11.001.
  23. Shedd GC, Blenis RC. Tiotropium for asthma: A summary of current guidelines and a case study. Journal of the American Association of Nurse Practitioners. 2018;30:460-463. DOI: 10.1097/ JXX.0000000000000053.
  24. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU et al.Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy Eur J Allergy Clin Immunol. 2009;64:778-783. doi: 10.1111/j.1398-9995.2008.01876.x.
  25. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. Engl J Med. 2010;363:1715-1726. DOI: 10.1056/ NEJMoa1008770.
  26. Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M et al. Tiotropium improves lung function , exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198-206. doi: 10.1016/j.rmed.2016.06.013.
  27. Paggiaro P, Beck E, Vandewalker M, Sigmund R, Math D, Seibold W et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. N Engl J Med. 2012;367:1198-1207. DOI: 10.1056/ NEJMoa120860.
  28. Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3:367-376. doi: 10.1016/S2213-2600(15)00031-4.
  29. Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova ZJ et al. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. Allergy Clin. Immunol. Pract. 2016;4:104-113. DOI: 10.1016/j. jaip.2015.08.017.
  30. Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R et al. Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination. Avoidance J Aerosol Med Pulm Drug Deliv. 2016;29:406-415. DOI: 10.1089/ jamp.2015.1260.

Views

Abstract - 35

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies